Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr

Part of paid clinical trials in Los Angeles, California.

Sponsor
Weill Medical College of Cornell University
Study ID
NCT05948657
Status
Recruiting

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • PSMA-PET CT — DIAGNOSTIC_TEST
    Patients will undergo PSMA-PET CT (Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography) at baseline, 12 month and 24 month time point.

Study Details

This study will be assessing the ability of PSMA-PET CT to determine the absence of clinically significant prostate cancer in patients on active surveillance (AS) with low risk and favorable intermediate-risk prostate cancer.

Key Dates

Start date
Feb 26, 2024
Status verified
Apr 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2028

Study Design

Enrollment
200 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC

Arms

  • Other: PSMA-PET CT
    Patients will undergo PSMA-PET CT (Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography) at baseline, 12 month and 24 month time point.

Primary Outcome Measure

Negative predictive value (NPV) [ Time Frame: Baseline ]

Central Contacts

Locations (4)

FacilityCityStateZIPSite coordinators
UCLALos AngelesCalifornia90005
Wayne Brisbane, M.D. (PRINCIPAL_INVESTIGATOR)
UCSFSan FranciscoCalifornia94143
Matthew Cooperberg, M.D. (PRINCIPAL_INVESTIGATOR)
Weill Cornell Medicine - New York Presbyterian HospitalNew YorkNew York10065
Timothy McClure, M.D.
Timothy McClure, M.D. (PRINCIPAL_INVESTIGATOR)
UH Cleveland Medical CenterClevelandOhio44106
Matt Ferrebee
Jonathan Shoag, M.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Los Angeles, CA

By condition

Related Studies